Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Other Topics

Abstract B74: Development of Salmonella-based vaccine against mesothelioma

Chen Xu
Chen Xu
HKU, Hong Kong.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.TUMIMM16-B74 Published March 2017
  • Article
  • Info & Metrics
Loading
Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 20-23, 2016; Boston, MA

Abstract

Purpose: Salmonella-based vaccine can provide protection against different kinds of cancer, whether used alone or used as a vehicle to deliver heterologous proteins. In this study, the functionality of a live Salmonella-p24 vaccine as a prophylactic anti-tumor vaccine against murine mesothelioma was analyzed.

Experimental Design: Malignant murine mesothelioma cell was engineered to express GAG, an HIV capsid protein, regarding as an artificial tumor associated antigen. Attenuated Salmonella enterica serovar Typhimurium aroA strain was modifed to encode p24, derived from GAG. BalB/C mice were orally immunized with Salmonella-p24 vaccine thrice at 2-week interval. P24-specific humoral and cellular immune responses were examined by ELISA and ELISPOT, respectively. Protection against the challenge with GAG-expressing mesothelioma was also evaluated after immunization.

Results: P24 antigen was successfully expressed in the cytoplasm of an attenuated Salmonella enterica serovar thyphimurium aroA strain. Immunization of wild-type BalB/C by oral gavage could elicit specific anti-p24 humoral and cellular immune response. In vivo protection studies revealed that over 80% of the treated mice remained free of GAG-mesothelioma after challenge, whereas all mice in control group developed tumor growth.

Conclusions: This p24-Salmonella vaccine could efficiently prevent GAG-expressing mesothelioma tumor growth in mice.

Citation Format: Chen Xu. Development of Salmonella-based vaccine against mesothelioma. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr B74.

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 5 (3 Supplement)
March 2017
Volume 5, Issue 3 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B74: Development of Salmonella-based vaccine against mesothelioma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B74: Development of Salmonella-based vaccine against mesothelioma
Chen Xu
Cancer Immunol Res March 1 2017 (5) (3 Supplement) B74; DOI: 10.1158/2326-6074.TUMIMM16-B74

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B74: Development of Salmonella-based vaccine against mesothelioma
Chen Xu
Cancer Immunol Res March 1 2017 (5) (3 Supplement) B74; DOI: 10.1158/2326-6074.TUMIMM16-B74
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Other Topics

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B197: Translational control in macrophages during inflammatory response
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
Show more Other Topics

Other Topics: Poster Presentations - Proffered Abstracts

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B197: Translational control in macrophages during inflammatory response
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
Show more Other Topics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement